UPDATE-(NASDAQ: NRSN) shares are moving up again more than 31% today on news of positive preliminary results from Alzheimer’s Biomarker Study.

Shares are $3.64 on more than 33 million in volume and closing in on 92,000 trades one hour after the open.

[mstock id=”73007″ asset=”nrsn”]

NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer’s Biomarker Study USA – English 


CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease (AD).

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.